RUBINSTEIN JULIE sold $879K of ADPT
RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.66 ($24.05–$25.57, $0.88M total) across 5 trades over 2026-10-19 to 2026-10-21 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
While the transaction is a primary disclosure, its modest size limits market impact. Traders may watch for any accompanying news that could amplify the effect.
Market read
The filing provides a fresh data point on insider activity for ADPT, offering a slight bearish cue but limited trading significance.
What to watch
Potential upcoming clinical data releases or partnership announcements could offset the sell pressure.
Background
Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑scheduled trades, reducing informational asymmetry.
Ticker impact
President and COO Julie Rubinstein sold 35,643 shares for $879K via a 10b5‑1 plan, reducing her stake to 377,802 shares.
potential modest price decline as market absorbs insider sell
Sale size is under $1M and executed through a pre‑arranged plan, limiting informational content; impact is limited but may trigger short‑term selling.
Market effects
Minimal effect on the broader biotech sector; insider sales are common and not indicative of sector trends.
No regional impact beyond ADPT's trading community.
Limited global relevance; only affects investors tracking ADPT.
Counterpoint
The sale could be purely mechanical under a 10b5‑1 plan, so it may not reflect any negative outlook.
Key entities
- InsiderJulie Rubinstein
President and COO of Adaptive Biotechnologies, reporting a sale of 35,643 shares.
